论文部分内容阅读
目的:评价丹参注射液在急性高血压脑出血中的治疗作用。方法:将受治的51例高血压脑出血患者(年龄50～78岁,平均612岁)在常规治疗基础上随机分成3组:丹参加胞二磷胆碱(CDPC)组(简称丹参组)、氨甲苯酸(PAMBA)加CDPC组(简称PAMBA组)和单用CDPC组。观察各组临床疗效、血肿吸收率、ADP诱导的血小板聚集率(ADPPag)和凝血酶原时间(PT)及肝、肾功能等情况。结果:采用格拉斯哥预后评分(GOS)方法,丹参治疗组中恢复良好和中等残疾(GR加MD)者占8571%,其他两组分别为4706%和6154%,经χ2检验,有显著性差异(P<005),丹参组临床疗效最佳;丹参组血肿吸收率与PAMBA组及CDPC组比较,经χ2检验,有显著性差异(P<005);丹参治疗组不影响血小板凝血功能,ADPPag、PT在正常范围。结论:丹参注射液是一种治疗急性高血压脑出血安全有效的药物,值得临床推广使用。
Objective: To evaluate the therapeutic effect of Danshen injection in acute hypertensive intracerebral hemorrhage. Methods: Fifty-one patients with hypertensive intracerebral hemorrhage (aged 50-78 years old, average 612 years old) were randomly divided into three groups: Danshen plus citicoline (CDPC) group (referred to as Danshen group) , Aminomethyl benzoate (PAMBA) plus CDPC group (PAMBA group) and CDPC group alone. The clinical efficacy, hematoma absorption rate, ADP induced platelet aggregation rate (ADPPag), prothrombin time (PT) and liver and kidney function were observed. Results: Glasgow’s prognostic score (GOS) was used in the treatment of salvia miltiorrhiza, 8571% of which were recovered well and moderately disabled (GR + MD). The other two groups were 4706% and 6154% respectively. There was significant difference (χ2 test) (P <0.05), the best clinical efficacy of Salvia miltiorrhiza group; Salvia miltiorrhiza absorption rate and PAMBA group and CDPC group compared by χ2 test, there was significant difference (P <005); Salvia treatment group does not affect platelet coagulation, ADPPag, PT in the normal range. Conclusion: Salvia miltiorrhiza injection is a safe and effective treatment of acute hypertensive intracerebral hemorrhage, which is worthy of clinical promotion.